report_lead_image_with_gradient.png
Q4 2026

Brain-Computer Interfaces: The Paralyzed Will Walk

Download this Report
To download this report, please complete the form below

PitchBook clients can access the full report and Excel data packs via the Research Center on the PitchBook Platform.

Beyond Neuralink: BCI opportunity extends across neuromodulation, bioelectronics, and surgical robotics

Brain-computer interface (BCI) VC deal activity has accelerated, while advances in commercialization are expanding the sector’s potential far beyond the traditional vision of implanted devices restoring movement and speech. PitchBook estimates that the broader BCI market generated $10.4 billion in revenue in 2026 and could reach $50.5 billion by 2046, with spinal cord stimulation, peripheral bioelectronic medicine, cochlear implants, and tremor treatment representing the largest opportunities.

VC-backed BCI companies raised $1.6 billion in the first nine months of 2026 alone, following $1.5 billion in 2025. Recent major financings include Synchron’s $200 million Series D, Science Corporation’s $230 million Series C, and Precision Neuroscience’s $250 million Series D. This analyst note examines the competitive landscape across invasive and noninvasive BCI technologies, emerging applications in psychiatry and TMS, and adjacent opportunities in surgical robotics.


BCI VC deal activity is accelerating.


Table of contents
Key takeaways 1
Segmentation methodology and landscape 2
Neuralink's vision 2
Total addressable market (TAM) 3
Deal activity and valuation 7
Due diligence 11
Deal sourcing 12
Technical insights 14
Appendix 14
References 17